Treatment in Esophagogastric Junction Cancer: Past, Present and Future

Publication date: Available online 20 September 2019Source: Cirugía Española (English Edition)Author(s): Carles Pericay, Ismael Macías-Declara, Virginia Arrazubi, Laia Vilà, Miguel MarínAbstractAdenocarcinomas of the gastroesophageal junction represent 27% of all gastric tumors. In recent years, it has been classified as an entity of its own, with specific treatments that are sometimes differentiated from gastric treatments. Treatment can be based on chemotherapy (CTx) or chemoradiotherapy (CRTx) that is administered preoperatively (neoadjuvant), postoperatively (adjuvant) or perioperatively. There are studies that have tested several treatment modalities, but there is currently no single protocolized sequence. The results point to an improvement in survival when we administer preoperative treatment, with evidence in favor of CRTx and CTx. Studies are already underway with targeted treatment that aim to increase the activity of traditional chemotherapy. In the next few years, we should know the role of immunotherapy in this group of patients.ResumenLos adenocarcinomas de la unión esofagogástrica representan un 27% de todos los tumores gástricos. En los últimos años se está clasificando como una entidad propia, con tratamientos específicos y en ocasiones diferenciados de los tratamientos de los adenocarcinomas de cuerpo gástrico. El esquema de tratamiento puede basarse en quimioterapia (...
Source: Cirugia Espanola - Category: Surgery Source Type: research

Related Links:

Endoscopic surveillance is currently recommended in patients with Barrett's esophagus (BE) to detect prevalent and incident dysplasia/esophageal adenocarcinoma. This strategy is underpinned by the concepts that (1) dysplasia can be treated endoscopically to prevent early gastric cancer (EAC),1 and (2) early-stage EAC (without symptomatic dysphagia and muscularis propria invasion) can be successfully treated (endoscopically) with excellent long-term survival.2
Source: Gastrointestinal Endoscopy - Category: Gastroenterology Authors: Tags: Original article Source Type: research
AbstractBackground.Alterations in the DNA damage response (DDR) pathway confer sensitivity to certain chemotherapies, radiation, and other DNA damage repair targeted therapies. BRCA1/2 are the most well‐studied DDR genes, but recurrent alterations are described in other DDR pathway members across cancers. Deleterious DDR alterations may sensitize tumor cells to poly (ADP‐ribose) polymerase inhibition, but there are also increasing data suggesting that there may also be synergy with immune checkpoint inhibitors. The relevance of DDR defects in gastrointestinal (GI) cancers is understudied. We sought to characterize DDR...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Gastrointestinal Cancer Source Type: research
Conclusion.These findings suggest that combination therapy with capecitabine and oxaliplatin as perioperative chemotherapy, followed by D2 gastrectomy, is effective and safe in late‐stage, locally advanced gastric cancer. Although enrollment exceeded the 47 patients required to identify an increase in the ORR by 15% (from 40% to 55%), results did not meet the primary endpoint.
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Chinese Edition, Clinical Trial Results, Gastrointestinal Cancer Source Type: research
TAS-102 improved overall survival, compared with placebo, in patients with metastatic gastric or gastroesophageal junction (GEJ) cancer.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
ConclusionOur111In-anti-CDH17 Mab D2101 depicted CDH17-positive gastric cancer xenografts in vivo and has the potential to be an imaging probe for the diagnosis of primary lesions and lymph-node metastasis in gastric cancer.
Source: Annals of Nuclear Medicine - Category: Nuclear Medicine Source Type: research
Conditions:   Gastric Adenocarcinoma;   Advanced Cancer Interventions:   Drug: Apatinib;   Drug: POF Sponsor:   Fujian Cancer Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Several studies have reported the risk of progression to gastric adenocarcinoma (GAC) in patients with gastric dysplasia (GD); however, the findings are controversial. We performed a systematic review and meta-analysis to study the incidence rate of GAC among patients with GD. Using a comprehensive search strategy, we systematically searched online databases including PubMed, Scopus, EMBASE, Cochrane Library, and Web of Science databases for identifying all relevant original articles through inception until July 2018. Cochran Q and I2 tests were used to assess heterogeneities between included studies. The incidence rates o...
Source: Journal of Clinical Gastroenterology - Category: Gastroenterology Tags: CLINICAL REVIEW Source Type: research
Conclusion: Reinforcement on duodenal stump using laparoscopic single purse-string suture during laparoscopic radical gastrectomy is simple and effective and could avoid the incidence of duodenal stump leakage to some extent.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsOur findings suggest that ANTXR1 is a promising candidate for preclinical and clinical evaluation for gastric adenocarcinoma immunotherapy.
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
L, Marín M Abstract Adenocarcinomas of the gastroesophageal junction represent 27% of all gastric tumors. n recent years, it has been classified as an entity of its own, with specific treatments that are sometimes differentiated from gastric treatments. Treatment can be based on chemotherapy (CTx) or chemoradiotherapy (CRTx) that is administered preoperatively (neoadjuvant), postoperatively (adjuvant) or perioperatively. There are studies that have tested several treatment modalities, but there is currently no single protocolized sequence. The results point to an improvement in survival when we administer p...
Source: Cirugia eEspanola - Category: Surgery Authors: Tags: Cir Esp Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Chemotherapy | Gastric (Stomach) Cancer | Gastroenterology | Immunotherapy | Maca | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Study | Surgery